Serum Basal Thyroglobulin Measured by a Second-Generation Assay Correlates with the Recombinant Human Thyrotropin-Stimulated Thyroglobulin Response in Patients Treated for Differentiated Thyroid Cancer

被引:94
作者
Spencer, Carole [1 ]
Fatemi, Shireen [2 ]
Singer, Peter [1 ]
Nicoloff, John [1 ]
LoPresti, Jonathan [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA
[2] So Calif Permanente Med Grp, Dept Endocrinol, Panorama City, CA USA
关键词
FOLLOW-UP; CIRCULATING THYROGLOBULIN; INCREASING INCIDENCE; UNITED-STATES; CARCINOMA; MANAGEMENT; PAPILLARY; SENSITIVITY; HORMONES; RHTSH;
D O I
10.1089/thy.2009.0338
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recombinant human thyrotropin (rhTSH) stimulation is frequently used to assess the disease status of patients treated for differentiated thyroid cancer (DTC) when basal (unstimulated) thyroglobulin (b-Tg) is below the assay sensitivity limit. The objective of this study was to determine relationships between the b-Tg and the 72-hour rhTSH-stimulated Tg (rhTSH-Tg) using a second-generation immunochemiluminometric assay with a functional sensitivity of 0.05 ng/mL (mu g/L). Methods: Serum Tg was measured in paired b-Tg and rhTSH-Tg specimens from 1029 rhTSH tests performed on 849 TgAb-negative patients during long-term monitoring for DTC. Results: Basal Tg correlated with rhTSH-Tg across b-Tg concentrations ranging from 0.05 to 1000 ng/mL (mu g/L) (r = 0.85, p < 0.0001). The b-Tg concentration was unrelated to age, sex, basal TSH, 72-hour TSH, or the Tg fold response (rhTSH-Tg/b-Tg). Further, only 2/655 (0.3%) tests with b-Tg below 0.1 ng/mL (mu g/L) had rhTSH-Tg above 2.0 ng/mL (mu g/L) (2.9 and 3.8 ng/mL [mu g/L], respectively). Thirty-three patients with three or more rhTSH tests performed over a 2- to 5-year period displayed high indexes of individuality for both the 72-hour TSH and the Tg fold response (indexes of individuality 0.30 and 0.38, respectively). Basal Tg measured using a first-generation assay with a functional sensitivity of 0.9 ng/mL (mu g/L) failed to reliably detect an rhTSH-Tg response above 2.0 ng/mL (mu g/L). Conclusions: An rhTSH-Tg response above 2.0 ng/mL (mu g/L) was highly unlikely when b-Tg was below 0.1 ng/mL (mu g/L). Second-generation b-Tg measurements correlated with the degree of rhTSH-Tg stimulation and thus the likelihood of having rhTSH-Tg above the customary cut-off of 2.0 ng/mL (mu g/L), whereas b-Tg measured by a first-generation assay did not. Correlations between four different assays showed that the use of a fixed Tg cut-off was influenced by assay selection. Patients receiving repetitive rhTSH tests had highly reproducible rhTSH-Tg/b-Tg fold responses, suggesting that repetitive testing is unnecessary and that second-generation measurement of b-Tg trends without rhTSH stimulation would be satisfactory for the long-term monitoring of most patients with DTC.
引用
收藏
页码:587 / 595
页数:9
相关论文
共 43 条
[1]  
[Anonymous], 2001, Biological variation: from principles to practice
[2]  
Baloch Z, 2003, THYROID, V13, P57
[3]   Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels [J].
Castagna, M. G. ;
Brilli, L. ;
Pilli, T. ;
Montanaro, A. ;
Cipri, C. ;
Fioravanti, C. ;
Sestini, F. ;
Capezzone, M. ;
Pacini, F. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (01) :76-81
[4]   Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma [J].
Castagna, MG ;
Pinchera, A ;
Marsili, A ;
Giannetti, M ;
Molinaro, E ;
Fierabracci, P ;
Grasso, L ;
Pacini, F ;
Santini, F ;
Elisei, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :4047-4050
[5]   Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005 [J].
Chen, Amy Y. ;
Jemal, Ahmedin ;
Ward, Elizabeth M. .
CANCER, 2009, 115 (16) :3801-3807
[6]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[7]   Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].
Davies, L ;
Welch, HG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167
[8]  
FeldtRasmussen U, 1996, ANN BIOL CLIN-PARIS, V54, P337
[9]   Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission [J].
Fugazzola, L ;
Mihalich, A ;
Persani, L ;
Cerutti, N ;
Reina, M ;
Bonomi, M ;
Ponti, E ;
Mannavola, D ;
Giammona, E ;
Vannucchi, G ;
Di Blasio, AM ;
Beck-Peccoz, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (07) :3201-3208
[10]   Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma [J].
Giovanella, Luca ;
Ceriani, Luca ;
Suriano, Sergio ;
Ghelfo, Antonella ;
Maffioli, Marco .
CLINICAL ENDOCRINOLOGY, 2008, 69 (04) :659-663